Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.
about
Targeting glutamate uptake to treat alcohol use disordersCeftriaxone protects against tobramycin nephrotoxicityPharmacokinetics of ceftriaxone in plasma and bone of patients undergoing hip or knee surgery.Ceftriaxone-associated nephrolithiasis in children.Gallbladder pseudolithiasis caused by ceftriaxone in young adult.Is Ceftriaxone-Induced Biliary Pseudolithiasis Influenced by UDP-Glucuronosyltransferase 1A1 Gene Polymorphisms?In vivo activity and pharmacokinetics of ziracin (SCH27899), a new long-acting everninomicin antibiotic, in a murine model of penicillin-susceptible or penicillin-resistant pneumococcal pneumonia.Enhanced killing of antibiotic-resistant bacteria enabled by massively parallel combinatorial geneticsA multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.Reduction in biliary excretion of ceftriaxone by diclofenac in rabbits.Antimicrobial activity of ceftriaxone, cefotaxime, desacetylcefotaxime, and cefotaxime-desacetylcefotaxime in the presence of human serum.Ceftriaxone-Induced Gallstones: Case Report and Literature ReviewMoxifloxacin versus Clindamycin/Ceftriaxone in the management of odontogenic maxillofacial infectious processes: A preliminary, intrahospital, controlled clinical trial.A fatal adverse effect of cefazolin administration: severe brain edema in a patient with multiple meningiomas.Modulation of the intestinal flora of mice by parenteral treatment with broad-spectrum cephalosporins.Use of third-generation cephalosporins. Anaerobes.Use of third-generation cephalosporins. Pseudomonas.Use of third-generation cephalosporins. Enterobacteriaceae.Ceftriaxone in treatment of serious infections. Urinary tract infections.Pharmacokinetics of ceftriaxone.Single-dose intra-procedural ceftriaxone during endoscopic ultrasound fine-needle aspiration of pancreatic cysts is safe and effective: results from a single tertiary center.Third generation cephalosporins: safety profiles after 10 years of clinical use.Oral delivery of ionic complex of ceftriaxone with bile acid derivative in non-human primates.Safety of ceftriaxone in paediatrics: a systematic review protocol.Drug-induced liver injury associated with high-dose ceftriaxone: a retrospective cohort study adjusted for the propensity score.Cefodizime in serum and skin blister fluid after single intravenous and intramuscular doses in healthy volunteers.Ceftriaxone: a beta-lactamase-stable, broad-spectrum cephalosporin with an extended half-life.Vancomycin-resistant enterococci in acute myeloid leukemia and myelodysplastic syndrome patients undergoing induction chemotherapy with idarubicin and cytarabine.Ceftriaxone (single dose) versus cefoxitin (multiple doses): success and failure of antibiotic prophylaxis in 1052 cesarean sections.Reversible Ceftriaxone-Induced Pseudolithiasis in an Adult Patient with Maintenance Hemodialysis.A case of ceftriaxone-associated biliary pseudolithiasis in an elderly patient with renal dysfunction.Antimicrobial activity of ceftriaxone compared with cefotaxime in the presence of serum albumin.Sonographic assessment of ceftriaxone-associated biliary pseudolithiasis in Chinese children.Gallbladder and urinary tract precipitations associated with ceftriaxone therapy in children: a prospective study.Lack of probenecid effect on nonrenal excretion of ceftriaxone in anephric patients.Progressive Pseudolithiasis Associated with the Intravenous Administration of Ceftriaxone in Patients with Central Nervous System Infections.Risk factors of ceftriaxone-associated biliary pseudolithiasis in adults: influence of renal dysfunction.Usefulness of Endoscopic Managements in Patients with Ceftriaxone-Induced Pseudolithiasis Causing Biliary Obstruction.Fasting and bed rest, even for a relatively short period, are risk factors for ceftriaxone-associated pseudolitiasis.Ceftriaxone-associated pancreatitis captured on serial computed tomography scans.
P2860
Q27002488-A35CB242-1037-40FD-AA9B-6BC114EFB4CDQ28369285-8DF55226-7971-4242-B7C3-4EC0AE5A5967Q30317265-CD0E6D81-907C-4ECB-8E8B-1865883981E0Q30437094-592DEEC8-1F1B-4DCD-8097-BB6ACAA93009Q30471969-B1E0DCC9-1852-4D0A-84C1-EB09569C2F9FQ30472794-831437B4-7E2F-4F7D-B7B5-2F3B76461204Q33979192-0C354C20-7853-49B9-BD48-174C7FACA6F3Q34119921-4B54FC88-2C73-4238-AD91-A5AACE02039BQ35138146-7A12D648-4DE7-4C55-8ADA-F9D59C9688D6Q35348393-9E10EE58-3DB4-4AFD-8015-8275B5AAA0FAQ35540563-8D95A4D0-D701-415D-83D1-03652D07053AQ35618178-8A6B86AB-2105-4321-B416-F40E8294AD16Q36328173-0CB45057-6C9F-432D-A56A-B03854C2A293Q36585734-B5B74284-631B-4288-8C3B-7D793C8454BDQ36753861-C956D52F-4DAB-4739-BB03-88B3B2A472CCQ37381365-5E72A389-7F83-42D6-A2CE-90801540BDABQ37381368-F66B1740-FC68-4B0D-835C-6176D2E5EB64Q37381380-25C1AEA8-588A-4140-8078-0EF518016A35Q37381422-BB3278AD-B7FC-4CCD-A2E5-3044E4747FFEQ37381432-58729F89-0A03-4699-9A33-14C1A8ED1E75Q37657139-E11D4A91-9E88-4C1E-88BC-6781B21FC2B2Q37928639-6443627C-B0EC-4E51-9A87-BE695E9AF26BQ38454518-799EC32A-7101-4F21-8FA2-D9071040DC16Q38615554-7AA2AC44-858E-4D57-955E-19C116874B89Q39812362-45CF7C9B-7641-4EFA-B8E0-BD368534E941Q39829105-28A4E1DE-7B8F-4027-B197-04BB086C4E3AQ39835731-9F41F8CA-F38C-4776-AB27-608E2CBE068AQ40274934-BBACBBE8-462F-4796-9E07-FDC61AA3D35EQ40724917-889916C2-C1DD-49A3-93D3-74F496E80BF2Q40914194-B53B324C-D46A-49EA-9B3E-209D528E5FD4Q40954111-2FF5138E-0EE9-453D-A130-9404F0A3579DQ42151894-18D2909B-CED6-4A3F-9285-8A1B304EAA99Q42758519-6CEC7A2C-75B5-4BE8-A72A-B652B5CC85EDQ44789840-C419C8C1-7AAE-482C-ABCB-07FB7642F19CQ44945407-4C304ACC-17DD-4C04-B476-5A93208E5E4BQ47107169-C3B3A3C4-5CE7-48CB-A055-B8841EFF9626Q47611194-17F22DA2-2ACC-483E-B503-597CDA822C0CQ48138014-BCC3B6F9-4EAF-4560-A21F-20ACC64DC17CQ51304051-A5C09923-4023-4BB4-B811-E69886FA24D0Q52682293-D61522F6-F77E-4F60-9ECD-C027417E3773
P2860
Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.
description
1984 nî lūn-bûn
@nan
1984年の論文
@ja
1984年論文
@yue
1984年論文
@zh-hant
1984年論文
@zh-hk
1984年論文
@zh-mo
1984年論文
@zh-tw
1984年论文
@wuu
1984年论文
@zh
1984年论文
@zh-cn
name
Ceftriaxone. A review of its a ...... roperties and therapeutic use.
@en
type
label
Ceftriaxone. A review of its a ...... roperties and therapeutic use.
@en
prefLabel
Ceftriaxone. A review of its a ...... roperties and therapeutic use.
@en
P2093
P1433
P1476
Ceftriaxone. A review of its a ...... roperties and therapeutic use.
@en
P2093
D M Richards
T M Speight
P304
P356
10.2165/00003495-198427060-00001
P577
1984-06-01T00:00:00Z
P6179
1007874029